【答案】：Caspase(cysteine aspartic acid specific protease)酶：是一组结构类似、与细胞凋亡有关的蛋白酶家族。是存在于胞质溶胶中的结构上相关的半胱氨酸蛋白酶家族，其活性位点是半胱氨酸残基，它们能特异地断开底物蛋白某一天门冬氨酸残基后面的肽键，从而选择性的切割蛋白质，使底物蛋白激活或失活。
Here we show that caspase-6, a cysteine-aspartic protease of the apoptosis cascade, serves as an important host factor for efficient coronavirus replication. We demonstrate that caspase-6 cleaves coronavirus nucleocapsid proteins, generating fragments that serve as interferon antagonists, thus facilitating...
是一类半胱氨酸蛋白水解酶(cysteine aspartic acid specific protease),简称胱天蛋白酶(caspase) (2)Bcl-2蛋白家族(是线虫ced-9的同源物) 根据其功能可以分为两大类: ①抑制凋亡的Bcl-2: Bcl-2、Bcl-xL、Bcl-w、Mcl-1 能阻止线粒体外膜的通透化,保护细胞免于凋亡。
MBPrecombinant proteinHerein, the expression of recombinant cysteine-rich atypical buckwheat (Fagopyrum esculentum) aspartic protease (FeAPL1) in five Escherichia coli strains differing in their expression capabilities is presented. It was shown that the expression success depended highly on the choice of...
The intracellular signaling pathway that triggers apoptosis has been studied well; the signal flows down the 'cascade' that consists of multiple caspases (Cysteine‐ASPartic proteASE) such as caspase 9 or 3 encoded by 来自 Wiley 喜欢 0 阅读量: 10 作者: None DOI: 10.1111/gtc.12302 年份...
Here we show that a cysteine-aspartic protease of the apoptosis cascade, caspase-6, serves as an essential host factor for efficient coronavirus replication. We demonstrate that caspase-6 cleaves coronavirus nucleocapsid (N) proteins, generating N fragments that serve as interferon (IFN) antagonists,...
The present disclosure generally pertains to methods of treating myocardial infarct involving administering a platelet anti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion therapy. In certain embodiments, the platelet anti-aggregate is at least one P2Y12 receptor antagonist or Glycoprotein...
The present disclosure generally pertains to methods of treating myocardial infarct involving administering a platelet anti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion therapy. In certain embodiments, the platelet anti-aggregate is at least one P2Y12 receptor antagonist or Glycoprotein...
The present disclosure generally pertains to methods of treating myocardial\ninfarct involving administering a platelet\nanti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion\ntherapy. In certain embodiments, the platelet anti-aggregate is\nat least one P2Y12 receptor antagonist or ...
MBPrecombinant proteinHerein, the expression of recombinant cysteine-rich atypical buckwheat (Fagopyrum esculentum) aspartic protease (FeAPL1) in five Escherichia coli strains differing in their expression capabilities is presented. It was shown that the expression success depended highly on the choice of...